 | • レポートコード：MRC2Q12-16793 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、高分子CDMOのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 高分子CDMOのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 高分子CDMOの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 高分子CDMOのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの高分子CDMOの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の高分子CDMOの売上および2028年までの予測に焦点を当てています。 高分子CDMOのグローバル主要企業には、WuXi Biologics、GenScript Biotech Corporation、Zhenge Biotech、Samsung Biologics、Catalent, Inc.、Cambrex Corp.、AGC Biologics、Recipharm AB、Siegfried Holding、LabCorp Drug Development、FUJIFILM Diosynth Biotechnologiesなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 高分子CDMO市場は、タイプとアプリケーションによって区分されます。世界の高分子CDMO市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 API開発、API製造 【アプリケーション別セグメント】 製薬会社、バイオテクノロジー会社 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 高分子CDMO製品概要 - タイプ別市場（API開発、API製造） - アプリケーション別市場（製薬会社、バイオテクノロジー会社） - 調査の目的 ・エグゼクティブサマリー - 世界の高分子CDMO販売量予測2017-2028 - 世界の高分子CDMO売上予測2017-2028 - 高分子CDMOの地域別販売量 - 高分子CDMOの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別高分子CDMO販売量 - 主要メーカー別高分子CDMO売上 - 主要メーカー別高分子CDMO価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（API開発、API製造） - 高分子CDMOのタイプ別販売量 - 高分子CDMOのタイプ別売上 - 高分子CDMOのタイプ別価格 ・アプリケーション別市場規模（製薬会社、バイオテクノロジー会社） - 高分子CDMOのアプリケーション別販売量 - 高分子CDMOのアプリケーション別売上 - 高分子CDMOのアプリケーション別価格 ・北米市場 - 北米の高分子CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の高分子CDMO市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの高分子CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の高分子CDMO市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の高分子CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の高分子CDMO市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の高分子CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の高分子CDMO市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの高分子CDMO市場規模（タイプ別、アプリケーション別） - 主要国別の高分子CDMO市場規模（トルコ、サウジアラビア） ・企業情報 WuXi Biologics、GenScript Biotech Corporation、Zhenge Biotech、Samsung Biologics、Catalent, Inc.、Cambrex Corp.、AGC Biologics、Recipharm AB、Siegfried Holding、LabCorp Drug Development、FUJIFILM Diosynth Biotechnologies ・産業チェーン及び販売チャネル分析 - 高分子CDMOの産業チェーン分析 - 高分子CDMOの原材料 - 高分子CDMOの生産プロセス - 高分子CDMOの販売及びマーケティング - 高分子CDMOの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 高分子CDMOの産業動向 - 高分子CDMOのマーケットドライバー - 高分子CDMOの課題 - 高分子CDMOの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Macromolecular CDMO estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Macromolecular CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Macromolecular CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Macromolecular CDMO is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Macromolecular CDMO include WuXi Biologics, GenScript Biotech Corporation, Zhenge Biotech, Samsung Biologics, Catalent, Inc., Cambrex Corp., AGC Biologics, Recipharm AB and Siegfried Holding, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Macromolecular CDMO companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Macromolecular CDMO market. Further, it explains the major drivers and regional dynamics of the global Macromolecular CDMO market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
WuXi Biologics
GenScript Biotech Corporation
Zhenge Biotech
Samsung Biologics
Catalent, Inc.
Cambrex Corp.
AGC Biologics
Recipharm AB
Siegfried Holding
LabCorp Drug Development
FUJIFILM Diosynth Biotechnologies
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Macromolecular CDMO Segment by Type
API Development
API Manufacturing
Macromolecular CDMO Segment by Application
Pharmaceutical Company
Biotechnology Company
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Macromolecular CDMO market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Macromolecular CDMO market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Macromolecular CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Macromolecular CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Macromolecular CDMO revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Macromolecular CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Macromolecular CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including WuXi Biologics, GenScript Biotech Corporation, Zhenge Biotech, Samsung Biologics, Catalent, Inc., Cambrex Corp., AGC Biologics, Recipharm AB and Siegfried Holding, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Macromolecular CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Macromolecular CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Macromolecular CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Macromolecular CDMO Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 API Development
1.2.3 API Manufacturing
1.3 Market by Application
1.3.1 Global Macromolecular CDMO Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Macromolecular CDMO Market Perspective (2017-2028)
2.2 Macromolecular CDMO Growth Trends by Region
2.2.1 Macromolecular CDMO Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Macromolecular CDMO Historic Market Size by Region (2017-2022)
2.2.3 Macromolecular CDMO Forecasted Market Size by Region (2023-2028)
2.3 Macromolecular CDMO Market Dynamics
2.3.1 Macromolecular CDMO Industry Trends
2.3.2 Macromolecular CDMO Market Drivers
2.3.3 Macromolecular CDMO Market Challenges
2.3.4 Macromolecular CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Macromolecular CDMO Players by Revenue
3.1.1 Global Top Macromolecular CDMO Players by Revenue (2017-2022)
3.1.2 Global Macromolecular CDMO Revenue Market Share by Players (2017-2022)
3.2 Global Macromolecular CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Macromolecular CDMO Revenue
3.4 Global Macromolecular CDMO Market Concentration Ratio
3.4.1 Global Macromolecular CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Macromolecular CDMO Revenue in 2021
3.5 Macromolecular CDMO Key Players Head office and Area Served
3.6 Key Players Macromolecular CDMO Product Solution and Service
3.7 Date of Enter into Macromolecular CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Macromolecular CDMO Breakdown Data by Type
4.1 Global Macromolecular CDMO Historic Market Size by Type (2017-2022)
4.2 Global Macromolecular CDMO Forecasted Market Size by Type (2023-2028)
5 Macromolecular CDMO Breakdown Data by Application
5.1 Global Macromolecular CDMO Historic Market Size by Application (2017-2022)
5.2 Global Macromolecular CDMO Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Macromolecular CDMO Market Size (2017-2028)
6.2 North America Macromolecular CDMO Market Size by Type
6.2.1 North America Macromolecular CDMO Market Size by Type (2017-2022)
6.2.2 North America Macromolecular CDMO Market Size by Type (2023-2028)
6.2.3 North America Macromolecular CDMO Market Share by Type (2017-2028)
6.3 North America Macromolecular CDMO Market Size by Application
6.3.1 North America Macromolecular CDMO Market Size by Application (2017-2022)
6.3.2 North America Macromolecular CDMO Market Size by Application (2023-2028)
6.3.3 North America Macromolecular CDMO Market Share by Application (2017-2028)
6.4 North America Macromolecular CDMO Market Size by Country
6.4.1 North America Macromolecular CDMO Market Size by Country (2017-2022)
6.4.2 North America Macromolecular CDMO Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Macromolecular CDMO Market Size (2017-2028)
7.2 Europe Macromolecular CDMO Market Size by Type
7.2.1 Europe Macromolecular CDMO Market Size by Type (2017-2022)
7.2.2 Europe Macromolecular CDMO Market Size by Type (2023-2028)
7.2.3 Europe Macromolecular CDMO Market Share by Type (2017-2028)
7.3 Europe Macromolecular CDMO Market Size by Application
7.3.1 Europe Macromolecular CDMO Market Size by Application (2017-2022)
7.3.2 Europe Macromolecular CDMO Market Size by Application (2023-2028)
7.3.3 Europe Macromolecular CDMO Market Share by Application (2017-2028)
7.4 Europe Macromolecular CDMO Market Size by Country
7.4.1 Europe Macromolecular CDMO Market Size by Country (2017-2022)
7.4.2 Europe Macromolecular CDMO Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Macromolecular CDMO Market Size (2017-2028)
8.2 Asia-Pacific Macromolecular CDMO Market Size by Type
8.2.1 Asia-Pacific Macromolecular CDMO Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Macromolecular CDMO Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Macromolecular CDMO Market Share by Type (2017-2028)
8.3 Asia-Pacific Macromolecular CDMO Market Size by Application
8.3.1 Asia-Pacific Macromolecular CDMO Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Macromolecular CDMO Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Macromolecular CDMO Market Share by Application (2017-2028)
8.4 Asia-Pacific Macromolecular CDMO Market Size by Region
8.4.1 Asia-Pacific Macromolecular CDMO Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Macromolecular CDMO Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Macromolecular CDMO Market Size (2017-2028)
9.2 Latin America Macromolecular CDMO Market Size by Type
9.2.1 Latin America Macromolecular CDMO Market Size by Type (2017-2022)
9.2.2 Latin America Macromolecular CDMO Market Size by Type (2023-2028)
9.2.3 Latin America Macromolecular CDMO Market Share by Type (2017-2028)
9.3 Latin America Macromolecular CDMO Market Size by Application
9.3.1 Latin America Macromolecular CDMO Market Size by Application (2017-2022)
9.3.2 Latin America Macromolecular CDMO Market Size by Application (2023-2028)
9.3.3 Latin America Macromolecular CDMO Market Share by Application (2017-2028)
9.4 Latin America Macromolecular CDMO Market Size by Country
9.4.1 Latin America Macromolecular CDMO Market Size by Country (2017-2022)
9.4.2 Latin America Macromolecular CDMO Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Macromolecular CDMO Market Size (2017-2028)
10.2 Middle East & Africa Macromolecular CDMO Market Size by Type
10.2.1 Middle East & Africa Macromolecular CDMO Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Macromolecular CDMO Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Macromolecular CDMO Market Share by Type (2017-2028)
10.3 Middle East & Africa Macromolecular CDMO Market Size by Application
10.3.1 Middle East & Africa Macromolecular CDMO Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Macromolecular CDMO Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Macromolecular CDMO Market Share by Application (2017-2028)
10.4 Middle East & Africa Macromolecular CDMO Market Size by Country
10.4.1 Middle East & Africa Macromolecular CDMO Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Macromolecular CDMO Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 WuXi Biologics
11.1.1 WuXi Biologics Company Details
11.1.2 WuXi Biologics Business Overview
11.1.3 WuXi Biologics Macromolecular CDMO Introduction
11.1.4 WuXi Biologics Revenue in Macromolecular CDMO Business (2017-2022)
11.1.5 WuXi Biologics Recent Developments
11.2 GenScript Biotech Corporation
11.2.1 GenScript Biotech Corporation Company Details
11.2.2 GenScript Biotech Corporation Business Overview
11.2.3 GenScript Biotech Corporation Macromolecular CDMO Introduction
11.2.4 GenScript Biotech Corporation Revenue in Macromolecular CDMO Business (2017-2022)
11.2.5 GenScript Biotech Corporation Recent Developments
11.3 Zhenge Biotech
11.3.1 Zhenge Biotech Company Details
11.3.2 Zhenge Biotech Business Overview
11.3.3 Zhenge Biotech Macromolecular CDMO Introduction
11.3.4 Zhenge Biotech Revenue in Macromolecular CDMO Business (2017-2022)
11.3.5 Zhenge Biotech Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Details
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Macromolecular CDMO Introduction
11.4.4 Samsung Biologics Revenue in Macromolecular CDMO Business (2017-2022)
11.4.5 Samsung Biologics Recent Developments
11.5 Catalent, Inc.
11.5.1 Catalent, Inc. Company Details
11.5.2 Catalent, Inc. Business Overview
11.5.3 Catalent, Inc. Macromolecular CDMO Introduction
11.5.4 Catalent, Inc. Revenue in Macromolecular CDMO Business (2017-2022)
11.5.5 Catalent, Inc. Recent Developments
11.6 Cambrex Corp.
11.6.1 Cambrex Corp. Company Details
11.6.2 Cambrex Corp. Business Overview
11.6.3 Cambrex Corp. Macromolecular CDMO Introduction
11.6.4 Cambrex Corp. Revenue in Macromolecular CDMO Business (2017-2022)
11.6.5 Cambrex Corp. Recent Developments
11.7 AGC Biologics
11.7.1 AGC Biologics Company Details
11.7.2 AGC Biologics Business Overview
11.7.3 AGC Biologics Macromolecular CDMO Introduction
11.7.4 AGC Biologics Revenue in Macromolecular CDMO Business (2017-2022)
11.7.5 AGC Biologics Recent Developments
11.8 Recipharm AB
11.8.1 Recipharm AB Company Details
11.8.2 Recipharm AB Business Overview
11.8.3 Recipharm AB Macromolecular CDMO Introduction
11.8.4 Recipharm AB Revenue in Macromolecular CDMO Business (2017-2022)
11.8.5 Recipharm AB Recent Developments
11.9 Siegfried Holding
11.9.1 Siegfried Holding Company Details
11.9.2 Siegfried Holding Business Overview
11.9.3 Siegfried Holding Macromolecular CDMO Introduction
11.9.4 Siegfried Holding Revenue in Macromolecular CDMO Business (2017-2022)
11.9.5 Siegfried Holding Recent Developments
11.10 LabCorp Drug Development
11.10.1 LabCorp Drug Development Company Details
11.10.2 LabCorp Drug Development Business Overview
11.10.3 LabCorp Drug Development Macromolecular CDMO Introduction
11.10.4 LabCorp Drug Development Revenue in Macromolecular CDMO Business (2017-2022)
11.10.5 LabCorp Drug Development Recent Developments
11.11 FUJIFILM Diosynth Biotechnologies
11.11.1 FUJIFILM Diosynth Biotechnologies Company Details
11.11.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.11.3 FUJIFILM Diosynth Biotechnologies Macromolecular CDMO Introduction
11.11.4 FUJIFILM Diosynth Biotechnologies Revenue in Macromolecular CDMO Business (2017-2022)
11.11.5 FUJIFILM Diosynth Biotechnologies Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer